- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
17 result(s) found for: Plasmid.
Displaying page 1 of 1.
EudraCT Number: 2011-005538-20 | Sponsor Protocol Number: BA2011/15/02 | Start Date*: 2012-05-15 | |||||||||||||||||||||
Sponsor Name:BioAlliance Pharma | |||||||||||||||||||||||
Full Title: SAFETY AND EFFICACY OF INTRAMUSCULAR ELECTROTRANSFER OF PLASMID AMEP IN PATIENTS SUFFERING FROM ADVANCED OR METASTATIC MELANOMA: AN OPEN-LABEL PHASE I/II CLINICAL TRIAL THE AIMM STUDY (AMEP IN MET... | |||||||||||||||||||||||
Medical condition: Treatment of patients suffering from advanced or metastatic melanoma (stages III, IV) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: SI (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003491-41 | Sponsor Protocol Number: AG-CLI-0206-LTFU | Start Date*: 2016-12-12 | |||||||||||
Sponsor Name:AnGes Inc. | |||||||||||||
Full Title: A Long Term Follow-up Study of AMG0001 in Subjects with Critical Limb Ischemia | |||||||||||||
Medical condition: Critical limb ischemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001129-34 | Sponsor Protocol Number: AG-CLI-0206 | Start Date*: 2014-11-24 | |||||||||||
Sponsor Name:AnGes Inc. | |||||||||||||
Full Title: A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AMG0001 IN SUBJECTS WITH CRITICAL LIMB ISCHEMIA | |||||||||||||
Medical condition: Critical limb ischemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) BE (Prematurely Ended) HU (Completed) NL (Prematurely Ended) PL (Prematurely Ended) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003415-22 | Sponsor Protocol Number: AP-W-CLI-2018-8 | Start Date*: 2019-03-22 | |||||||||||
Sponsor Name:Aurealis Oy | |||||||||||||
Full Title: A Phase 1/2A clinical study to evaluate the safety, tolerability and efficacy of single and repeated doses of AUP1602-C as topical treatment of diabetic foot ulcers | |||||||||||||
Medical condition: Diabetic foot ulcers | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001340-22 | Sponsor Protocol Number: BHT-3009-03 | Start Date*: 2005-08-12 |
Sponsor Name:Bayhill Therapeutics | ||
Full Title: BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS | ||
Medical condition: Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarde... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) FI (Prematurely Ended) SK (Completed) CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-002849-40 | Sponsor Protocol Number: DermHivImm | Start Date*: 2006-03-29 |
Sponsor Name:Swedish Institute for Infectious Disease Control | ||
Full Title: Active immunotherapy against HIV during highly active anti-retroviral therapy followed by repeated treatment interruptions, VAC 09. | ||
Medical condition: Treatment of HIV infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-002359-18 | Sponsor Protocol Number: PEDVAC | Start Date*: 2008-04-23 | |||||||||||
Sponsor Name:Swedish Institute for Infectious Disease Control | |||||||||||||
Full Title: DNA vaccination in HIV-vertically infected children | |||||||||||||
Medical condition: Pazienti con infezione verticale da HIV di eta' compresa tra 4 -16 anni di ambo i sessi. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004838-15 | Sponsor Protocol Number: ENTHERE | Start Date*: 2014-08-13 |
Sponsor Name:Mª Carmen Fariñas Álvarez. Hospital Universitario Marques de Valdecilla | ||
Full Title: Intestinal colonization by multiresistant enterobacteria in patients with kidney and liver transplantation: multicentre cohort study and randomized, controlled, open clinical trial. | ||
Medical condition: Colonization by multiresistant enterobacteria in patients who underwent liver and renal transplants | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-009863-75 | Sponsor Protocol Number: CEAEP_2009-05-29 | Start Date*: 2009-08-26 | |||||||||||
Sponsor Name:Karolinska Institutet/ Hospital | |||||||||||||
Full Title: El-porCEA: Assessment of safety and immunogenicity of intradermal electroporation of tetwtCEA DNA in patients with colorectal cancer. | |||||||||||||
Medical condition: Colorectal carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022960-10 | Sponsor Protocol Number: CVC-202 | Start Date*: 2011-03-30 | |||||||||||
Sponsor Name:ChronTech Pharma AB | |||||||||||||
Full Title: A Phase II Open-Label, Randomized, Parallel group, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C in Combination with Electroporation followed by Standard of Care in Chroni... | |||||||||||||
Medical condition: Treatment of chronic infections caused by hepatitis C virus genotype 1 strains | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004120-21 | Sponsor Protocol Number: LX01-315 | Start Date*: 2008-02-27 | |||||||||||
Sponsor Name:Vical Incorporated | |||||||||||||
Full Title: A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metas... | |||||||||||||
Medical condition: Recurrent metastatic melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Ongoing) NL (Prematurely Ended) BE (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004753-16 | Sponsor Protocol Number: HEH-SF-02 | Start Date*: 2018-02-01 | |||||||||||
Sponsor Name:Department of Surgery, Herlev Hospital | |||||||||||||
Full Title: Intraperitoneal administration of fosfomycin, metronidazole and molgramostim versus intravenous conventional antibiotics for perforated appendicitis – a pivotal quasi-randomized controlled trial | |||||||||||||
Medical condition: We wish to investigate if intraoperative intraperitoneal administration of fosfomycin, metronidazole and rhGM-CSF followed by oral antibiotic for three days is as effective as the current intraveno... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005772-16 | Sponsor Protocol Number: HEH-SF-01 | Start Date*: 2016-06-22 | ||||||||||||||||
Sponsor Name:Department of Surgery, Herlev Hospital | ||||||||||||||||||
Full Title: The safety and pharmacokinetics of intraperitoneal administration of granulocyte-macrophage colony-stimulating factor, fosfomycin, and metronidazole in patients undergoing appendectomy for uncompli... | ||||||||||||||||||
Medical condition: We intend to investigate the safety of treating secondary infectious peritonitis due to uncomplicated appendicitis with intraperitoneally administered fosfomycin, metronidazole and GM-CSF. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-002901-33 | Sponsor Protocol Number: CVC-201 | Start Date*: 2007-08-10 | |||||||||||
Sponsor Name:Tripep AB | |||||||||||||
Full Title: A Phase I/IIa Open-Label, Dose Ranging, Parallel, Safety, Tolerability and Efficacy Study of i.m. Administered ChronVac-C® in Combination with Electroporation in Chronic Hepatitis C Virus Genotype ... | |||||||||||||
Medical condition: Treatment of chronic infections caused by hepatitis C virus genotype 1 strains | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003734-20 | Sponsor Protocol Number: COV-1/2-01 | Start Date*: 2021-02-03 | |||||||||||
Sponsor Name:Takis S.r.l. | |||||||||||||
Full Title: A Phase I/II study to assess the safety and immunogenicity of COVID-eVax, a candidate plasmid DNA vaccine for COVID-19, in healthy adult volunteers. | |||||||||||||
Medical condition: COVID-19 prevention. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000563-69 | Sponsor Protocol Number: IPCT003 | Start Date*: 2021-06-04 |
Sponsor Name:Ilya Pharma AB | ||
Full Title: A Randomized, Double-Blind, Placebo-controlled, Parallel, Exploratory Phase 2a Study to Evaluate Safety and Biological Effect on Wound Healing of ILP100 in Subjects with Diabetic Foot Ulcers | ||
Medical condition: Diabetic foot ulcers a systemic complication in diabetes mellitus type 1 or 2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002844-10 | Sponsor Protocol Number: SCIB1-002 | Start Date*: 2019-01-24 |
Sponsor Name:Scancell Ltd | ||
Full Title: A Phase 2, Multicenter, Open-Label Study of SCIB1 in Patients with Advanced Unresectable Melanoma Receiving Pembrolizumab | ||
Medical condition: Advanced unresectable melanoma. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.